KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Change in Receivables (2025 - 2026)

Teva Pharmaceutical Industries filings provide 2 years of Change in Receivables readings, the most recent being -$78.0 million for Q1 2026.

  • On a quarterly basis, Change in Receivables rose 70.45% to -$78.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $125.0 million, a 177.16% increase, with the full-year FY2025 number at -$173.0 million, down 170.61% from a year prior.
  • Change in Receivables hit -$78.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from -$264.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of -$78.0 million in Q1 2026 to a low of -$264.0 million in Q1 2025.